News
66 Drug Samples From Himachal Declared Substandard in Major CDSCO Alert
A CDSCO monthly alert has flagged 66 drug samples from 46 Himachal-based pharma firms as “Not of Standard Quality,” including critical medicines for cancer, cardiac care, psychiatric treatment, infections, and diabetes. The findings raise serious concerns over manufacturing standards in one of India’s largest pharma hubs.
In a significant monthly alert issued by the Central Drugs Standard Control Organization (CDSCO), 66 drug samples manufactured by 46 pharmaceutical companies in Himachal Pradesh have been classified as “Not of Standard Quality” (NSQ). The findings have raised serious concerns about gaps in the state’s large pharmaceutical ecosystem. These samples form part of a wider national list of 211 failed medicines, which also includes essential drugs used for cancer, cardiac care, infections, psychiatric treatment, and diabetes.
Several key industrial clusters—Baddi, Barotiwala, Nalagarh, Kala Amb, Solan, Paonta Sahib, Una, and Kangra—have come under scrutiny. Regulators are particularly alarmed by firms with repeated failures, including one unit in Nalagarh with seven failed samples, and two units in Paonta Sahib that reported an equal number of substandard batches.
Beyond Himachal, another 145 failed samples originated from Gujarat, Haryana, Punjab, Jammu, Andhra Pradesh, Madhya Pradesh, West Bengal, Maharashtra, and other states, signalling a wider quality-control challenge within India’s pharmaceutical supply chain.
Of the 211 substandard samples, 63 were declared NSQ by the Central Drugs Laboratory, while 148 failed testing at state drug laboratories. The products were found lacking in critical parameters such as assay, dissolution, identification, disintegration, content uniformity, particulate matter, sterility, and pH levels. Many of these defects are considered high-risk and often point to systemic lapses in manufacturing or non-compliance with Good Manufacturing Practices (GMP).
The alert has dealt a blow to Himachal Pradesh’s reputation as one of Asia’s largest pharmaceutical hubs—particularly since 31% of all failed samples in the national list originate from the state. Industry experts warn that repeated quality lapses could erode trust in the region’s manufacturing standards at a time when India is positioning itself as a global pharmacy.
Responding swiftly, State Drug Controller Manish Kapoor confirmed that notices have been issued to all defaulting firms, and immediate market recall of the failed batches has been ordered. The department has also begun re-sampling, factory inspections, GMP audits, and “risk-based inspections,” particularly targeting units with multiple violations, to identify systemic issues and implement corrective measures.
CDSCO, in coordination with state regulators, is intensifying market surveillance to protect public health and ensure that medicines reaching patients meet required safety and quality benchmarks.
